Taxotere-5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells

Anti-Cancer Drugs

Volumn 16, Issue 3, 2005, Pages 309-316

  Fischel, Jean Louis ^a   Ferrero, Jean Marc ^a   Formento, Patricia ^a   Ciccolini, Joseph ^b   Renée, Nicole ^a   Formento, Jean Louis ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b School of Pharmacy   (France)

Author keywords

5 DFUR; Prostate cancer; Taxotere; Xeloda

Indexed keywords

CAPECITABINE; DOCETAXEL; FAS ANTIGEN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DOXIFLURIDINE; ENZYME INHIBITOR; FLOXURIDINE; TAXOID;

ARTICLE; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; DRUG ANTAGONISM; DRUG COMBINATION; DRUG SCREENING; ENZYMOLOGY; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FLOXURIDINE; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 14144253915     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200503000-00010     Document Type: Article

References (32)

1. Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, et al. Phase I accelerated dose escalation and pharmacokinetic (PK) study of capecitabine and cisplatin (CP) in head and neck cancer patients. Proc Am Soc Clin Oncol 2002; 21:108a.
2. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566-575.
3. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
4. Cassata A, Procoplo G, Alu M, Ferrari L, Ferrario E, Beretta E, et al. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer. Tumori 2001; 87:364-371.
5. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86:1367-1372.
6. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
7. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzyme concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
8. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-237.
9. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
10. Nishimura G, Tereda I, Kobayashi T, Ninomiya L, Kitagawa H, Fushida S, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002; 9:479-482.
11. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
12. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000; 18:343-354.
13. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002; 20:2616-2623.
14. Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, et al. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9:4735-4742.
15. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol. 2003; 170:1709-1716.
16. Moyer P. New treatment hope for prostate cancer. Lancet Oncol 2004; 5:5.
17. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942.
18. Chou T, Talalay P. Quantitative analysis of dose-effects relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 1984; 22:27-55.
19. Spears CP, Gustavsson BG. Methods for thymidylate synthase pharmacodynamics: serial biopsy, free and total TS, FdUMP and dUMP, and H4PPteGlu and CH2-H4PteGlu assays. Adv Exp Med Biol 1988; 244:97-106.
20. Kubota Y, Miura T, Moriyama M, Noguchi S, Matsuzaki J, Takebayashi S, et al. Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin Cancer Res 1997; 3:973-976.
21. Vindelov L, Christensen IJ. An integrated set of methods for routine flow cytometric DNA analysis. Methods Cell Biol 1990; 33:127-137.
22. Marchetti S, Chazal M, Dubreuil A, Fischel JL, Etienne MC, Milano G. Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. Br J Cancer 2001; 85:439-445.
23. Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, et al. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther 2001; 1:133-139.
24. El-Rayes BF, Black CA, Ensley JF. Hormone-refractory prostate cancer responding to capecitabine. Urology 2003; 61:462.
25. Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 2002; 1:923-927.
26. Backus HH, Dukers DF, van Groeningen CJ, Vos W, Bloemana E, Wouters D, et al. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001; 12:209-216.
27. Piechocki PM, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res 2002; 8:870-877.
28. Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 2003; 63:8563-8572.
29. Degli Esposti M, Dive C. Mitochondrial membrane permeabilisation by Bax/Bak. Biochem Biophys Res Commun 2003; 304:455-461.
30. 1 cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002; 48:6-13.
31. Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995; 31A:1299-1305.
32. Longley DB, Harkin DP, Johnston PG. 5-Flurouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.